Impact of liver fibrosis and clinical characteristics on dose-adjusted serum methadone concentrations

• Published in: Journal of addictive diseases 2022
• Main Authors: Chalabianloo, Fatemeh, Høiseth, Gudrun, Vold, Jørn Henrik, Johansson, Kjell Arne, Kringen, Marianne K, Dalgard, Olav, Ohldieck, Christian, Druckrey-Fiskaaen, Karl Trygve, Aas, Christer Frode, Løberg, Else-Marie, Bramness, Jørgen Gustav, Fadnes, Lars T
• Format: Article
• Language: Norwegian
• ISSN: 1055-0887; 1545-0848

Background There is limited knowledge on the causes of large variations in serum methadone concentrations and dose requirements. Objectives We investigated the impact of the degree of liver fibrosis on dose-adjusted steady-state serum methadone concentrations. Methods We assessed the clinical and laboratory data of 155 Norwegian patients with opioid use disorder undergoing methadone maintenance treatment in outpatient clinics in the period 2016–2020. A possible association between the degree of liver fibrosis and dose-adjusted serum methadone concentration was explored using a linear mixed-model analysis. Results When adjusted for age, gender, body mass index, and genotypes of CYP2B6 and CYP3A5, the concentration-to-dose ratio of methadone did not increase among the participants with liver fibrosis (Coefficient: 0.70; 95% CI: −2.16, 3.57; P: 0.631), even among those with advanced cirrhosis (−0.50; −4.59, 3.59; 0.810). Conclusions Although no correlation was found between the degree of liver stiffness and dose-adjusted serum methadone concentration, close clinical monitoring should be considered, especially among patients with advanced cirrhosis. Still, serum methadone measurements can be considered a supplement to clinical assessments, taking into account intra-individual variations.